China Traditional Chinese Medicine (570 HK): Disaster as Offer Lapses, Potential Deal Break Price
This deal break caught many, including me, off guard. There are lessons to be learnt and questions to be asked. Shareholders will have a bruising...
1.5k Views
Primer: Consun Pharmaceutical (1681 HK) - Apr 2026
Dominant market leader in China's Traditional Chinese Medicine (TCM) for kidney diseases, with its flagship product, Uremic Clearance Granule,...
157 Views
APAC Healthcare Weekly (March 22) – Hengrui, Microport Neuro, Celltrion, Samsung Bio, Sun Pharma
Celltrion signed KRW375B biologics CMO deal with a global pharma company. Samsung Bioepis expands biosimilar collaboration with Sandoz. 40+ Indian...
358 Views
APAC Healthcare Weekly (Mar 23)- Kissei, Alteogen, Junshi Biosciences, Celltrion, Lunit, HLB
​Kissei Pharma initiates additional P3 trial. Junshi Biosciences' drug got indication expansion. AstraZeneca partners with Alteogen. Celltrion aims...
635 Views
HSCI / HK Connect (March 2026) Post-Event Review: What Worked, What Didn't
HK Connect Mar 2026 implementation cycle is completing. ADD reversed the WAI drawdown at implementation. DELETE continuation worked post...
268 Views